Kalaris Therapeutics, Inc. insider trading

KLRSNASDAQ

$2.70-0.15 (-5.26%)as of Oct 2, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (-61.9%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
Date	Category	Person	Role	Action	Amount	Change in holding

Open market purchase

Open market sell

Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium

Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Unlock quarterly net flow

Key players

VSVikas SinhaSee Remarks3.2519%of company
NFNapoleone FerraraDirector2.1172%of company
SCSamir Chandrakant PatelDirector1.482%of company
DBDiana BrainardChief Executive Officer0.1321%of company
EMEdward MillerGeneral Counsel0.0906%of company
MFMatthew FeinsodChief Medical Officer0.0169%of company
AOAmy O'Leary VandekopVP, Corporate Controller0.004%of company
BRBrett R. HagenChief Accounting Officer0.00%of company
SASrinivas AkkarajuDirectorNot reportedof company
SOSamsara Opportunity Fund, L.P.10% OwnerNot reportedof company

AI Activity Analysis

Premium

Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto

Company	Insider / role	Action	ΔOwn	Avg price	Amount
KLRS	Samsara BioCapital, L.P.10% Owner	Open market purchase$1.18M	+1.9%	$4.83	$1.18M	May 20, 2026	May 22, 2026
KLRS	Brett R. HagenChief Accounting Officer	Open market sell$12.9K	-100.0%	$6.72	$12.9K	Mar 20, 2026	Mar 23, 2026
KLRS	Samsara Opportunity Fund, L.P.10% Owner	Open market purchase$5M	+3.9%	$10.42	$5M	Dec 18, 2025	Feb 17, 2026

End of history · 3 transactions